Free access to abstracts at PubMed

1. Epstein JI, Hutchins GM: Subepicardial aneurysms: A rare complication of myocardial infarction. Am J Med 75: 639-44, l983.

2. Epstein JI, Sears DL, Tucker RS, Eagan JW: Carcinoma of the esophagus with adenoid cystic differentiation. Cancer 53: ll3l-ll36,l984.

3. Epstein JI, White CL, Mendelsohn G: Factor VIII related antigen and glial fibrillary acidic protein immunoreactivity in the differential diagnosis of central nervous system hemangioblastomas. Am J Clin Pathol 81: 285-92, l984.

4. Epstein JI, Mendelsohn G: Squamous carcinoma of the foot arising in association with longstanding verrucous hyperplasia in a patient with congenital lymphedema. Cancer 54: 943-947, l984.

5. Epstein JI, Hutchins GM: Granulomatous prostatitis: Distinction among allergic, nonspecific, and posttransurethral resection lesions. Human Pathology 15: 8l8-825, l984.

6. Epstein JI, Eggleston JC: Immunohistochemical localization of prostate-specific acid phosphatase and prostate-specific antigen in stage A2 adenocarcinoma of the prostate: Prognostic implications. Human Pathology 15: 853-859, l984.

7. Epstein JI, Berry SJ, Eggleston JC: Nuclear roundness factor: A predictor of progression in untreated state A2 prostate cancer. Cancer 54: l666 -l67l, l984.

8. Epstein JI, Urmacher C: A cutaneous neoplasm with neural differentiation. Am J Dermatopathol : 59l-593, l984.

9. Epstein JI, Erlandson RA, Rosen PP: Nodal blue nevi: A study of three cases. Am J Surg Pathol : 907-9l5, l984.

10. Epstein JI, Lieberman P: Mucinous adenocarcinomas of the prostate gland. Am J Surg Pathol :299-307, l985.

11. Epstein JI, Woodruff J: Prostatic carcinomas with endometrioid features:A light microscopic and immunohistochemical study of ten cases. Cancer 57: 111-119, l986.

12. Epstein JI, Budin R: The presence of keratin and epithelial membrane antigen immunoreactivity in non-neoplastic fibrous pleural lesions: Implications for the diagnosis of desmoplastic mesothelioma. Hum Pathol 17: 514-519, l986.

13. Christensen WN, Long DM, Epstein JI: Cerebellopontine angle lipoma. Hum Pathol 17: 739-743, l986.

14. Epstein JI, Paull G, Eggleston JC, Walsh PC: Prognosis of untreated stage Al prostatic carcinoma: A study of 94 cases with extended follow-up. J Urol 136: 837-839, l986.

15. Epstein JI, Kuhajda FP, Lieberman PH: Prostate specific acid phosphatase immunoreactivity in adenocarcinomas of the urinary bladder. Hum Pathol 17: 939-942, l986.

16. Oesterling JE, Epstein JI, Walsh PC: The inability of adrenal androgens to stimulate the adult human prostate: An autopsy evaluation of men with hypogonadotrophic hypogonadism and panhypopituitarism. J Urol 136: l030-l034, l986.

17. Epstein JI, Oesterling JE, Eggleston JC, Walsh PC: Frozen section detection of lymph node metastases in prostatic carcinoma: Accuracy in grossly uninvolved pelvic lymphadenectomy specimens. J Urol 136: 20. 1234-1237,l986.

18. Epstein JI, Ambinder RF, Kuhajda FP, Pearlman SH, Reuter VE, Mann RB: Localized herpes simplex lymphadenitis. Am J Clin Pathol 86: 444-448, l986.

19. Maria BL, Cafferty LL, Singer HS, Epstein JI, Carson BS: Diffuse leptomeningeal seeding from a spinal cord glioblastoma in a child with neurofibromatosis. J Neurooncology 4: 159-163, l986.

20. Oesterling JE, Epstein JI, Gearhart JP: Transitional cell carcinoma of the urinary bladder in an adolescent with Turners syndrome. J Urol 137: 398-400, l987.

21. Cafferty L, Epstein JI: Primary liposarcoma of the right atrium. Hum Pathol 18: 408-410, l987.

22. Cho KR, Epstein JI: Metastatic prostatic carcinoma to supradiaphragmatic lymph nodes: A clinicopathologic and immunohistochemical study. Am J Surg Pathol 11:457-463, l987.

23. Oesterling JE, Epstein JI, Walsh PC: Long-term autopsy findings following radical prostatectomy. Urology 29: 584-588, l987.

24. Oesterling JE, Brendler CB, Epstein JI, Kimball AW, Walsh PC: Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathologic stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol 138:92-98, l987.

25. Zinreich SJ, Wang H, Epstein JI, Brem H, Anderson JH, Rosenbaum AE. Carotid bifurcation imaging model for more accurately comparing imaging techniques. Acta Radiologica Supplementum 369: 24-28, l986.

26. Walsh PC, Epstein JI, Lowe FC: Potency following radical prostatectomy with wide unilateral excision of the neurovascular bundle. J Urol l38: 823-827, l987.

27. Shurbaji MS, Epstein JI: Testicular vasculitis: Implications for systemic disease. Hum Pathol 19: 186-189, l988.

28. Epstein JI, Oesterling JE, Walsh PC: The volume and anatomical location of residual tumor in radical prostatectomy specimens removed for stage Al prostate cancer. J Urol 139: 975-979, l988.

29. Oesterling JE, Chan DW, Epstein JI, Kimball AW, Jr., Bruzek DJ, Rock RC, Brendler CB, Walsh PC: Prostate-specific antigen in the pre-and post-operative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 139: 766-772, l988.

30. Robey SS, Olson JL, Brem H, Epstein JI: Posterior fossa neuroblastoma in an elderly man. Hum Pathol 19: 365-367, l988.

31. Epstein JI, Oesterling JE, Walsh PC: Tumor volume versus percent of specimen involved by tumor as predictors of progression in stage A prostate cancer. J Urol 139: 980-984, l988.

32. Mohler JL, Partin AW, Epstein JI, Lohr WD, Coffey DS. Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma: II. Standardization of methodology for histologic sections. J Urol 139: l085-1090, l988.

33. Cho KR, Olson JL, Epstein JI. Primitive rhabdomyosarcoma presenting with diffuse bone marrow involvement: An immunohistochemical and ultrastructural study. Modern Pathol 1: 23-28, l988.

34. Zinreich SJ, Kennedy DW, Malat J, Curtin HD, Epstein JI, Huff LC, Kumar AJ, Johns ME, Rosenbaum AE. Fungal sinusitis: diagnosis with CT and MR imaging. Radiol 169:439-444, 1988.

35. Tamargo RJ, Epstein JI, Brem H. Heterotransplantation of malignant human gliomas to the quadrigeminal cistern and subcutaneous space of neonatal rats. J Neurosurg 69:928-933, 1988.

36. Walsh PC, Oesterling JE, Epstein JI, Bruzek DJ, Rock RC, Chan DW. The value of prostate-specific antigen in the management of localized prostatic cancer. Prog Clin Biol Res 303:27-33, 1989.

37. Cho KR, Woodruff JD, Epstein JI. Leiomyoma of the uterus with multiple extrauterine smooth muscle tumors: A case report suggesting multifocal origin. Hum Pathol 20:80-83, 1989.

38. Burnett AL, Epstein JI, Marshall FF. Radical cystectomy for transitional cell carcinoma of the bladder: Long-term survival in high risk patients. Eur Urol 15:171-175, 1988.

39. Partin AW, Epstein JI, Cho KR, Gittelsohn AM, Walsh PC. Morphometric measurement of tumor volume and percent of gland involvement as predictors of pathologic stage in stage B prostate cancer. J Urol 141:341-345, 1989.

40. Tamargo RJ, Epstein JI, Reinhard CS, Chasin M, Brem H. Brain biocompatibility of a biodegradable, controlled-release polymer in rats. J Biomedical Materials Research 23:253-266, 1989.

41. Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 13:389-396, 1989.

42. Alexander RB, Maguire MG, Epstein JI Walsh PC. Pathologic stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate. J Urol 141:880-882, 1989.

43. Brem H, Epstein JI, Kader A, Tamargo RJ, Langer R, Leong KW. Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain. Selective Cancer Therapeutics 5:55-65,1989.

44. Mohler JL, Erozan YS, Walsh PC, Epstein JI. Fine needle core and apiration biopsy: A new method for diagnosis of prostatic carcinoma. Cancer 63:1846-1855, 1989.

45. Carter HB, Hamper UM, Sheth S, Sanders RC, Epstein JI, Walsh PC. Evaluation of transrectal ultrasound in the early detection of prostate cancer. J Urol 142:1008-1010,1989.

46. Salibi SS, Nauta HJW, Brem H, Epstein JI, Cho KR. Lipomeningioma: Report of three cases and review of the literature. J Neurosurg 25:122-126,1989.

47. Cho KR, Rosenshein NB, Epstein JI. Malignant rhabdoid tumor of the uterus. Int J Gyn Path 8:381-387, 1989.

48. Hruban RH, Bhagavan BS, Epstein JI. Massive retroperitoneal angiomyolipoma: A lesion that may be confused with well-differentiated liposarcoma. Am J Clin Pathol 92:805-808,1989.

49. Ronnett BM, Epstein JI. A case showing sclerosing adenosis and basal cell hyperplasia of the prostate. Am J Surg Pathol 13:866-872, 1989.

50. Partin AW, Walsh PC, Pitcock RV, Mohler JL, Epstein JI, Coffey DS. A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: A critical analysis. J Urol 142:1254-1258, 1989.

51. Maccumber MW, Hoffman PN, Wand GS, Epstein JI, Beschorner WE, Green WR. Ophthalmic involvement in aggressive histiocytosis X Opthalmology 97:22-27, 1990.

52. Larsen MP, Steinberg GD, Brendler CB, Epstein JI. Use of ulex europaeus agglutinin I (UEAI) to study vascular invasion in transitional cell carcinoma of bladder with submucosal invasion. Modern Pathol 1:83-88, 1990.

53. Christenson WN, Partin AW, Walsh PC, Epstein JI. Pathologic findings in stage A2 prostate cancer: Relation of tumor volume, grade and location to pathologic stage. Cancer 65:1021-1027, 1990.

54. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC. Prostate-specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume, and benign hyperplasia. J Urol 143: 747-752, 1990.

55. Oesterling JE, Brendler CB, Burgers JK, Marshall FF, Epstein JI. Advanced small cell carcinoma of the bladder: Successful treatment with combined radical cystoprostatectomy and adjuvent methotrexate, vinblastine, doxrubicin, and cisplatin chemotherapy. Cancer 65:1928-1990.

56. Quinn BD, Cho KR, Epstein JI. Relationship of severe dysplasia to stage B adenocarcinoma of the prostate. Cancer 65:2328-2337,1990.

57. Epstein JI, Cho KR, Quinn BD. Relationship of severe dysplasia to stage A (incidental) adenocarcinoma of the prostate. Cancer 65:2321-2327,1990.

58. Leonard MP, Canning DA, Epstein JI, Gearhart JP, Jeffs RD. Local tissue reaction of the subureteric injection of glutaraldehyde cross-linked collagen in humans. J Urol 143:1209-1212,1990.

59. North CA, North RB, Epstein JI, Piantadosi S, Wharam MD. Low grade cerebral astrocytomas: Survival and quality of life after radiotherapy. Cancer 66:6-14,1990.

60. Epstein JI. Evaluation of radical prostatectomy capsular margins of resection: The significance of margins designated as negative, closely approaching, and positive. Am J Surg Pathol 14:626-632,1990.

61. Hamper UM, Sheth S, Walsh PC, Epstein JI. Bright echogenic foci in early prostate cancer: A sonographic-pathologic correlation. Radiology 176:339-343, 1990.

62. Hamper UM, Epstein JI, Sheth S, Brennecke CM, Walsh PC, Sanders RC. Cystic lesions of the prostate gland: A sonographic-pathologic correlation. J Ultrasound Med 9:395-402, 1990.

63. Perlman EJ, Epstein JI. Blood group antigen expression in dysplasia and adenocarcinoma of the prostate. Am J Surg Path 14:810-818,1990.

64. Rifkin MD, Zerhouni EA, Gatsonis CA, Quint LE, Paushter DM, Epstein JI, Hamper U, Walsh PC, McNeil BJ. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer: Results of a multi-institutional cooperative trial. NEJM 323:621-626, 1990.

65. Schlegel PN, Epstein JI, Fishman EF, Brendler CB. Clinicopathological conference: Rapidly progressive bilateral ureteral obstruction. J Urol 144:957-959, 1990.

66. Partin AW, Walsh PC, Epstein JI, Leventhal BG, Gearhart JP. Nuclear morphometry as a predictor of response to therapy in Wilms tumor: A preliminary report. J Urol 144:952-954, 1990.

67. Epstein JI, Christensen WN, Steinberg GD, Carter HB. Comparison of DNA ploidy and nuclear size, shape, and chromatin irregularity in prostate carcinoma tissue sections versus smears. Analyt Quant Cytol Histol 12:352-358, 1990.

68. Oesterling JE, Epstein JI, Brendler CB. Myxoid malignant fibrous histiocytoma of the bladder. Cancer 66:1836-1842, 1990.

69. Epstein JI, Steinberg GD. The significance of low grade prostate cancer on needle biopsy: A radical prostatectomy study of tumor grade, volume, and stage of the biopsied and multifocal tumor. Cancer 66:1927-1932, 1990.

70. Hamper UM, Sheth S, Walsh PC, Holtz PM, Epstein JI. Carcinoma of the prostate: Value of transrectal sonography in detecting extension into the neurovascular bundle. AJR 155:1015-1019, 1990.

71. Carter HB, Partin AW, Epstein JI, Chan DW, Walsh PC. The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer. J Urol 144: 1167-1171, 1990.

72. Leonard MP, Partin AW, Epstein JI, Jeffs RD, Gearhart JP. Nuclear morphormetry as a prognostic indicator for pediatric genitourinary rhabdomyosarcoma: A preliminary investigation. J Urol 144:1222-1226, 1990.

73. Steinberg GD, Epstein JI, Piantadosi S, Walsh PC. Management of stage D1 adenocarcinoma of the prostate: The JHH Experience 1974-1987, J Urol 144:1425-1432, 1990.

74. Epstein JI: Relationship of dysplasia to prostate cancer. Semin Urol 8:2-8, 1990.

75. Kronthal AJ, Fishman EK, Sanders RC, Epstein JI, Kuhlman JE, Brendler CB. Uterine perforation simulating urachal carcinoma: CT diagnosis. Am J Rad 154:741-743, 1990.

76. Carter BS, Ewing CM, Ward SW, Treiger BF, Schalken JA, Epstein JI, Issacs WB. Allelic loss of chromosome 10q and 16q in human prostate cancer. Proc Natl Acad Sci USA 87:8751-8755, 1991.

77. Epstein JI. The evaluation of radical prostatectomy specimens per formed for carcinoma of the prostate. Therapeutic and prognostic implications. Path Ann 26(1):159-210, 1991.

78. Carter HB, Brem R, Tempany CM, Yang A, Epstein JI, Walsh PC, Zerhouni EA. Nonpalpable prostate cancer: Detection with MR imaging. Radiology 178:523-525, 1991.

79. Hamper UM, Sheth S, Walsh PC, Holtz PM, Epstein JI. Capsular transgression of prostatic carcinoma: Evaluation by transrectal ultrasonography with pathologic correlation. Radiology 178:791-795, 1991.

80. Christensen W, Walsh PC, Epstein JI. Prostatic duct adenocarcinoma: Findings at radical prostatectomy. Cancer 67:2118-2124, 1991.

81. Sheth S, Hamper UM, Walsh PC, Epstein JI. Stage A adenocarcinoma of the prostate: Transrectal US and sonographic-pathologic correlation. Radiology 179:35-39,1991.

82. Burnett AL, Epstein JI, Marshall FF. Adenocarcinoma of the urinary bladder: Classification and management. Urology 37:315-321, 1991.

83. Bastacky S, Walsh PC, Epstein JI. Needle biopsy associated tumor tracking of adenocarcinoma of the prostate. J Urol 145: 1003-1007, 1991.

84. Quinlan DM, Epstein JI, Carter BS, Walsh PC. Sexual function following radical prostatectomy: Influence of preservation of neurovascular bundles. J Urol 145: 998-1002, 1991.

85. Carter BS, Epstein JI, Isaacs WB. ras gene mutations in human prostate cancer. Cancer Res 50:6830-6832, 1990.

86. Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 145:405-409, 1991.

87. Hamper UM, Sheth S, Walsh PC, Holtz PM, Epstein JI. Stage B adenocarcinoma of the prostate: Transrectal US and pathologic correlation of non-malignant hypoechoic peripheral zone lesions. Radiology 180:101-104, 1991.

88. Wu TC, Mann RB, Epstein JI, MacMahon EM, Lee WA, Charache P, Hayward SD, Kurman RJ, Shah KH, Hayward GS, Ambinder RF. Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma: A morphologically distinctive target for detection of Epstein-Barr Virus in formalin-fixed carcinoma specimens. Am J Path 138:1461-1469, 1991.

89. Larsen MP, Carter HB, Epstein JI. Can stage A1 tumor extent be predicted by transurethral resection tumor volume, per cent, or grade? A study of 64 stage A1 radical prostatectomies with comparison to prostates removed for stage A2 and B disease. J Urol 146:1059-1063, 1991.

90. Tempany CMC, Rahmouni A, Epstein JI, Walsh PC, Zerhouni EA. Invasion of the neurovascular bundle by prostate cancer: Evaluation with MR imaging. Radiology 181:107-112, 1991.

91. North RB, Cutchis PN, Epstein JI, Long DM. Spinal cord compression complicating subarachnoid morphine infusion: Clinical and laboratory experience. J Neurosurgery 29:778-784, 1991.

92. Armas OA, Pizov G, Pitcock RV, Partin AW, Epstein JI. Nuclear morphometry of prostatic carcinoma: Comparison of computerized image analysis (CAS 200) versus video planimetry (DynaCell). Modern Pathol 4:763-769, 1991.

93. Gearhart JP, Partin AW, Leventhal B, Beckwith JB, Epstein JI. The use of nuclear morphometry to predict response to therapy in Wilm's tumor. Cancer 69:804-808,1992.

94. Mohler JL, Partin AW, Epstein JI, Becker RL, Mikel UV, Sesterhenn IA, Mostofi FK, Gleason DF, Sharief Y, Coffey DS. Prediction of prognosis in untreated stage A2 prostatic carcinoma. Cancer 69: 511-519, 1992.

95. Hall GS, Kramer CE, Epstein JI. Evaluation of radical prostatectomy specimens: A comparative analysis of various sampling methods. Am J Surg Pathol 16:315-324, 1992.

96. Brem H, Domb A, Lenartz D, Dureza C, Olivi A, Epstein JI. Brain biocompatibility of a biodgradable controlled release polymer consisting of anhydride copolymer of fatty acid dimer and sabacic acid. J Controlled Release 19:325-330, 1992.

97. Partin AW, Steinberg GD, Pitcock RV, Wu L, Piantadosi S, Coffey DS, Epstein JI. Use of nuclear morphometry, Gleason histologic scoring, clinical stage and age to predict disease-free survival among patients with prostate cancer. Cancer 70:161-168,1992.

98. Epstein JI, Pizov G, Steinberg GD, Carter HB, Pitcock BA, Armas OA, Partin A. Correlation of prostate cancer nuclear DNA, size, shape and Gleason grade with pathologic stage at radical prostatectomy. J Urol 148:87-91,1992.

99. Lee BR, Partin AW, Epstein JI, Quinlan DM, Gosling JA, Gearhart JP. A quantitative histological analysis of the dilated ureter of childhood. J Urol 148:1482-1486, 1992.

100. Epstein JI, Fynheer J. Acidic mucin in the prostate: can it differentiate adenosis from adenocarcinoma? Human Pathol 23: 1321-1325, 1992.

101. Epstein JI, Armas OA. Atypical basal cell hyperplasia of the prostate. Am J Surg Pathol 16:1205-1214, 1992.

102. Epstein JI. Cancer detected incidental to simple prostatectomy (stage A1). J Cell Biochem 16H (suppl):78-82, 1992.

103. Silver SA, Epstein JI. Adenocarcinoma of the colon simulating primary urinary bladder neoplasia: A report of nine cases. Am J Surg Pathol 17:171-178, 1993.

104. Tamargo RJ, Myseros J, Epstein JI, Yang MB, Chasin M, Brem H. Interstitial intracranial chemotherapy of the 9L gliosarcoma: Controlled release polymers for drug delivery to the brain. Cancer Res 53:329-333, 1993.

105. Borland, RN, Partin AW, Epstein JI, Brendler CB. The use of nuclear morphometry in predicting recurrence of transitional cell carcinoma. J Urol 149:272-275, 1993.

106. Rahmouni A, Yang A, Tempany C, Frenkel T, Epstein JI, Walsh PC, Leichner PK, Ricci C, Zerhouni E. Accuracy of in-vivo assessment of prostatic volume by MRI and transrectal ultrasonography. Computer Assissted Tomography 16:935-940, 1992.

107. Bova GS, Fox W, Epstein JI. Methods of radical prostatectomy specimen processing: A novel technique for harvesting fresh prostate cancer tissue and review of processing techniques. Mod Pathol 6:201-207, 1993.

108. Bastacky SI, Walsh PC, Epstein JI. Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage B adenocarcinoma of the prostate. Am J Surg Pathol 17:336-341,1993.

109. Partin AW, Getzenberg RH, CarMichael MJ, Vindivich D, Yoo J, Epstein JI, Coffey DS. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res 53:744-746, 1993.

110. Partin AW, Gearhart JP, Leonard MP, Leventhal BG, Yoo JK, Crooks D, Epstein JI, Beckwith JB. The use of nuclear morphometry to predict pediatric urologic malignancies: A review. Medical and Pediatric Oncology. 21:222-229, 1993.

111. Epstein JI, CarMichael M, Walsh, PC. Adenocarcinoma of the prostate invading the seminal vesicle: Definition and relation of tumor volume, grade, and margins of resection to prognosis. J Urol 149:1040-1045, 1993.

112. Gikas PW, Del Buono EA, Epstein JI. Florid hyperplasia of mesonephric remnants involving prostate and periprostatic tissue: Possible confusion with adenocarcinoma. Am J Surg Pathol 17:454-460, 1993.

113. Perlman EJ, Epstein JI, Pizov G, Long PP, Griffin CA. Cytogenetic and ploidy analysis of prostatic adenocarcinoma. Modern Pathology 6:348-352, 1993.

114. Tardif CP, Partin AW, Epstein JI, Mohler JL. Comparison of nuclear shape in aspirated and histologic specimens of prostatic carcinoma. Anal and Quant Cytology and Histology 14:474-482, 1993.

115. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression following radical retropubic prostatectomy. Cancer 71:3582-3593, 1993.

116. Kramer CE, Epstein JI. Nucleoli in low-grade prostate adenocarcinoma and adenosis. Hum Pathol 24:618-623, 1993.

117. Weinstein MH, Epstein JI. Significance of high grade prostatic intraepithelial neoplasia (PIN) on needle biopsy. Hum Pathol 24:624-629, 1993.

118. Epstein JI, Carmichael M, Partin AW, Walsh PC. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with five years follow-up. J Urol 149:1478-1481, 1993.

119. Epstein JI, Carmichael M, Pizov G, Walsh PC. Influence of capsular penetration on progression following radical prostatectomy: A study of 196 cases with long-term follow-up. J Urol 150:135-141, 1993.

120. Burnett AL, Tillman SL, Chang TSK, Epstein JI, Lowenstein CJ, Bredt DS, Snyder SH, Walsh PC. Immunohistochemical localization of nitric oxide synthase in the autonomic innervation of the human penis. J Urol 150:73-76, 1993.

121. Partin AW, Borland RN, Epstein JI, Brendler CB. Influence of wide excision of the neurovascular bundles on progression in tumors with capsular penetration. J Urol 150:142-148, 1993.

122. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer. J Urol 150:110-114, 1993.

123. Ronnette BM, CarMichael MJ, Carter HB, Epstein JI. Does prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels? J Urol 150:386-389, 1993.

124. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER. Androgen receptor gene mutations in human prostate cancer. PNAS 89:6319-6323, 1992.

125. Olivi A, Kim KD, Benedetti L, Epstein JI, Pinn L, Callegro L, Brem H. Ocular and brain biocompatibility of polymeric delivery materials prepared from ester derivatives of hyularonic acid. J Clin Material 13:163-168, 1993.

126. Bova GS, Carter BS, Bussemakers JG, Emi M, Yoshiyuki F, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, Isaacs WB. Homozygous deletion and frequent allelic loss of 8p22 loci in human prostate cancer. Cancer Research 53:3869-3873, 1993.

127. Epstein JI. PSAP and PSA as immunohistochemical markers. Urologic Clinics of North America 20:757-770, 1993.

128. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA following anatomical radical prostatectomy: The Johns Hopkins Experience after 10 years. Urologic Clinics of North America 1993.

129. Pound CR, Partin AW, Epstein JI, Simons JW, Marshall FF. Nuclear morphometry accurately predicts recurrence in clinically localized renal cell carcinoma. Urology 42:243-248, 1993.

130. Cadeddu JA, Pearson JD, Partin AW, Epstein JI, Carter, HB. Relationship between changes in prostate-specific antigen and prognosis of men with prostate cancer. Urol 42:383-389, 1993.

131. Burnett AL, Epstein JI, Gearhart JP. Spectrum of differentiation in pediatric epithelial tumors of the kidney: report of two cases. Urology 42:93-98, 1993.

132. Epstein JI, Walsh PC, CarMichael M, Brendler CB. Pathological and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer JAMA 271:368-374, 1994.

133. Sanda MG, Ayyagari SR, Jaffe EM, Epstein JI, Clift SL, Cohen LK, Dranoff G, Pardoll DM, Mulligan RC, Simons JW. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 151:622-628, 1994.

134. Brem H, Tamargo RJ, Olivi A, Pinn M, Weingart JD, Wharam M, Epstein JI. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg 80:283-290, 1994.

135. Partin AW, Lee BR, CarMichael M, Walsh PC, Epstein JI. Radical prostatectomy for high grade disease: A re-evaluation 1993. J Urol 151:1583-1586, 1994.

136. Epstein JI, CarMichael MJ, Partin AW. Small high grade adenocarcinomas of the prostate in radical prostatectomy specimens performed for non-palpable disease: pathogenic and clinical implications. J Urol 151:1587-1592, 1994.

137. McDowell PR, Fox W, Epstein JI. Is submission of remaining tissue necessary when incidental carcinoma of the prostate is found on transurethral resection? Hum Pathol 25:493-497, 1994.

138. Gaudin PB, Epstein JI. Adenosis of the Prostate: Histologic features in transurethral resection specimens. Am J Surg Pathol 18:863-870, 1994.

139. Murphy GP, Busch C, Abrahamsson PA, Epstein JI, et al. Histopathology of localized prostate cancer. Scand J Urol Nephrol Suppl 162:7-42, 1994.

140. Sgrignoli AR, Walsh PC, Steinberg GD, Steiner MS, Epstein JI. Prognostic factors in men with stage D1 prostate cancer: Identification of patients less likely to benefit from radical surgery. J Urol 152:1077-1081, 1994.

141. Veltri RW, Partin AW, Epstein JI, et al. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cellular Biochem, Suppl.19:249-258, 1994.

142. Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: The Johns Hopkins experience with tumors found on transurethral resection (stages T1A & T1B) and on needle biopsy (stage T1C). J Urol 152:1721-1729, 1994.

143. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J Urol 152:1831-1836, 1994.

144. Epstein JI. Prostatic intraepithelial neoplasia. Advances in Anatomic Pathology 1:123-134, 1994.

145. Epstein JI. Pathology of prostatic intraepithelial neoplasia and adenocarcinoma of the prostate: Prognostic influences of stage, tumor volume, grade, and margins of resection. Sem Onc 21:527-541, 1994.

146. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Evaluation of serum prostatic specific antigen velocity after radical prostatectomy to distinguish local recurrence versus distant metastases. Urology 43:649-659, 1994.

147. Bastacky S, Silver SA, Epstein JI. Composite cytologic smears of pelvic lymph nodes at time of radical prostatectomy to identify nodal metastases. Hum Pathol 25:1352-1359, 1994.

148. Schoenberg MP, Hakimi JM, Wang S, Bova GS, Epstein JI, Fischbeck KH, Isaacs WB, Walsh PC, Barrack ER. Microsatellite mucation (CAG 24-18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Comm 198:74-80, 1994.

149. Epstein JI, CarMichael M, Partin AW. OA-519 (fatty acid synthase) as an independent predictor of pathologic stage in adenocarcinoma of the prostate. Urology 45:86, 1994.

150. Partin AW, Yoo JK, Crooks D, Epstein JI, Beckwith JB, Gearhart JP. Prediction of disease-free survival after therapy in Wilms' tumor using nuclear morphometric techniques. J Ped Surg 29:456-460, 1994.

151. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PG, Bova GS, Hsieh WS, Isaacs WB, Nelson WG. Cytidine methylation of regulatory sequences near the -class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci 91:11733-11737, 1994.

152. Newmark JR, Newmark GM, Epstein JI, Marshall FF. Solitary late recurrence of renal cell carcinoma. Urology 43:725-728, 1994.

153. Murphy GP, Busch C, Abrahamsson PA, Epstein JI, et al. Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Scand J Urol Nephrol Suppl. 162:7-42, 115-127, 1994

154. Schoenberg M, Cairns P, Brooks JC, Marshall FF, Epstein JI, Isaacs WB, Sidransky O. Loss of chromosome 8p in collecting duct carcinoma (DC) of the kidney. Genes Chromosomes and Cancer 12:76-80, 1995.

155. Gearhart JP, Willmann JRQ, Beckwith JB, Epstein JI, Partin AW. Nuclear morphometric analysis of metastasis in Wilms' tumor after multimodal therapy: comparison with primary tumor. Urology 45:119-123, 1995.

156. CarMichael MJ, Veltri RW, Partin AW, Miller MC, Walsh PC, Epstein JI. Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol 153:1015-1019, 1995.

157. Bastacky SS, Wojno KJ, Walsh PC, CarMichael M, Epstein JI. Pathologic features of hereditary prostate cancer. J Urol 153:987-992, 1995.

158. Epstein JI . Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy Hum Pathol 26:223-229, 1995.

159. Wojno KJ, Epstein JI. The utility of basal cell specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer: a review of 228 cases. Am J Surg Pathol 19:251-260, 1995.

160. Judy KD, Olivi A, Bauhin KG, Domb A, Epstein JI, Colvin OM, Brem H. Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas J Neurosurg 82:481-486, 1995.

161. Gaudin PB, Epstein JI. Adenosis of the Prostate: Histologic features in needle biopsy specimens. Am J Surg Pathol 19:737-747, 1995.

162. Partin AW, Piantadosi S, Sanda MG, Epstein JI, Marshall FF, Mohler JL, Brendler CB, Walsh PC, Simons JW. Selection of men at high risk for recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 45:831-838, 1995.

163. Riopel MA, Polascik TJ, Partin AW, Walsh PC, Epstein JI. Pathologic findings and progression after radical prostatectomy in men less than 50 years old: A study of 140 cases. Urologic Oncology 1:80-83, 1995.

164. Kahane H, Sharp JW, Shuman GB, Dasilva G, Epstein JI. Utilization of high molecular weight cytokeratin on prostate biopsies in an independent laboratory. Urology 45:981-986, 1995.

165. Gearhart JP, Lee Br, Epstein JI, Partin AW, Goslin JA. A quantitative histological evaluation of the dilated ureter of childhood II: Ectopia, posterior urethral valves and prune belly syndrome. J Urol 153:172-176, 1995.

166. Epstein JI , Grignon DJ, Humphrey PA, McNeal JE, Sesterhenn IA, Troncoso P, Wheeler TM. Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia. Am J Surg Pathol 19:873-886,1995.

167. Cadeddu JA, Pearson JD, Lee B, Partin AW, Epstein JI, Carter HB. Relationship between changes in prostate-specific antigen and the percent of prostatic epithelium in men with benign prostatic hyperplasia. Urology 45:795-800,1995.

168. Berges RR, Vukanovic J, Epstein JI, CarMichael M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT. Implication of the cell kinetics changes during the progression of human prostatic cancer. Clin Cancer Res 1:473-480, 1995

169. Polascik TJ. Meng MV, Epstein JI, Marshall FF. Intraoperative sonography for evaluation and management of renal tumors: experience with 100 patients. J Urol 154:1676-1680, 1995.

170. Epstein JI. Adenosis (atypical adenomatous hyperplasia): Histopathology and relationship to carcinoma. Path Res Pract 191:888-898, 1995.

171. Gaudin PB, Wheeler TM, Epstein JI. Verumontanum mucosal gland hyperplasia (VMGH) in prostatic needle biopsy specimens: A mimic of low-grade prostatic adenocarcinoma. Am J Clin Pathol 104:620-626, 1995

172. Pressman EA, Zeidman SM, Reddy UM, Epstein JI, Brem H. Differentiating lymphocytic adenohypophysitis from pituitary adenoma in the peripartum patient. J Reproductive Medicine 40:251-259, 1995.

173. Van Den Berg C, Guan XY, Von Hoff D, Jenkins R, Bittner M, Griffin C, Kallioniemi O, Visakorpi T, McGill J, Herath J, Epstein JI, Sarosdy M, Meltzer P, Trent J. DNA sequence amplification in human prostate cancer identified by chromosome microdissection: Potential prognostic implications. Clin Cancer Res 1:11-18, 1995.

174. Rosin MP, Cairns P, Epstein JI, Schoenberg MP, Sidransky D. Partial allelotype of carcinoma in situ of the human bladder. Cancer Res 55:5213-5216, 1995.

175. Algaba F, Epstein JI, Fabus G, Helpap B, Nagle RB, Polito M. Working standards in prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Pathology, Research and Practice 191:836-837, 1995.

176. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT. Enhanced expression of bc1-2 and the progression of human and rodent prostatic cancer. Clin Cancer Res 2:389-398, 1996.

177. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy: A multivariate analysis of 721 men with long-term follow-up Am J Surg Pathol 20:286-292, 1996.

178. Schoenberg MP, Carter HB, Epstein JI. Ureteral frozen section analysis during cystectomy: A reassessment. J Urol 155:1218-1220, 1996

179. Brown C, Sauvageot J, Kahane H, Epstein JI. Cell proliferation and apoptosis in prostate cancer - Predictors of pathologic stage? Mod Pathol 9:205-209, 1996.

180. Nelson RS, Epstein JI. Prostatic carcinoma with abundant xanthomatous cytoplasm: Foamy gland carcinoma. Am J Surg Pathol 20:419-426, 1996.

181. Epstein JI. Pathologic evaluation of prostatic carcinoma: Critical information for the oncologist. Oncology 10:527-534, 1996.

182. Polascik TJ, Cairns P, Epstein, JI, et.al. Distal nephron tenal tumors: microsatellite allelotype. Cancer Research 56:1892-1895, 1996.

183. Algaba F, Epstein JI, Aldape HC, et al. Assessment of prostate carcinoma in core needle biopsy. Definition of minimal cirteria for the diagnosis of cancer in biopsy material: International Consultation on prostatic intraepithelial neoplasia and pathologic staging of prostatic carcinoma. Cancer 78:376-381, 1996.

184. Epstein JI. The diagnosis and reporting of adenocarcinoma of the prostate in needle core biopsy specimens. Cancer 78:350-356, 1996.

185. Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine (NE) differentiation in prostate cancer. Enhanced prediction of progression following radical prostatectomy. Hum Pathol 27:683-687, 1996.

186. Epstein JI, Walsh PC, Sanfilippo F. Clinical and cost impact of second opinion pathology review of prostate needle biopsies prior to radical prostatectomy. Am J Surg Pathol 20: 851-857, 1996.

187. Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148:1567-1576, 1996.

188. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Sokhom SP, Epstein JI, et al. Genetic Alterations in untreated metastases and androgen independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Research 56: 3091-3102, 1996.

189. McEntee MF, MF, Ssyring R, Epstein JI, Strandberg JD. Characterization of prostatic basal cell hyperplasia and neoplasia in aged macaques: Comparative pathology in human and non-human primates. Prostate 29:51-59, 1996.

190. Epstein JI. Pathological precursors of prostate cancer. Canadian J Urol 3 (suppl.):6-13, 1996.

191. Epstein JI. Predictive factors for progression of prostate cancer Canadian J Urol 3 (suppl): 74-79, 1996.

192. Epstein JI. Can significant prostate cancer be predicted preoperatively in men with stage T1 disease? Seminars in Oncology 14:165-173, 1996.

193. Smith RC, Partin AW, Epstein JI, Brendler CB. Extended follow-up of the influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer and extensive capsular perforation. J Urol 156:454-458, 1996.

194. Tran KP, Epstein JI. Mucinous adenocarcinoma with urinary bladder differentiation arising from the prostatic urethra: distinction from mucinous adenocarcinoma of the prostate. Am J Surg Pathol 20:1346-1350, 1996.

195. Epstein JI. Incidence and significance of positive margins in radical prostatectomy specimens. Urol Clin N Am 23:651-663, 1996.

196. Steiner G, Cairns P, Polascik TJ, Marshall FF, Epstein JI, et al. High-density mapping on chromosomal arm 1q in renal collecting duct carcinoma: region of minimal deletion at 1q32.1-32.2 Cancer Res 56:5044-5046, 1996.

197. Veltri RW, Miller MC, Partin AW, Coffey DS, Epstein JI. Ability to predict bio- chemical progression using Gleason score and a computer-generated qualtitative nuclear grade derived from cancer cell nuclei. Urology 48:685-691, 1996.

198. Taylor DC, Bhagavan BS, Larsen MP, Cox JA, Epstein JI. Papillary urothelial hyperplasia: a precursor to papillary neoplasms. Am J Surg Pathol 12:1481-1488, 1996.

199. Pannek J, Subong E, Jones KA, Marschke P, Epstein JI, et al. The role of free/total PSA in the prediction of final pathological stage for men with clinically localized prostate cancer. Urology (supplement):51-54, 1996.

200. Doehring CB, Sanda MG, Partin JS, Juo H, Beaty TH, Epstein JI, Hill G, Walsh PC. Histopathologic characterization of hereditary benign prostatic hyperplasia. Urology 48:650, 1996.

201. Epstein JI, Sauvageot J. Do close but negative margins in radical prostatectomy specimens increase the risk of post-operative progression? J Urol 157:241-243, 1997.

202. Weinstein LJ, Epstein JI, Edlow D, Westra W. Static image analysis of skin specimens: The application of telepathology to frozen section evaluation. Hum Pathol 28:30-35, 1997.

203. Weinstein MH, Epstein JI. Telepathology diagnosis of prostate needle biopsies. Hum Pathol 28:22-29, 1997.

204. Sipos EP, Tamargo RJ, Epstein JI, North RB. Primary intracerebral small-cell osteosarcoma in an adolescent girl: report of a case. J Neuro-Onc 32:169-174, 1997.

205. DiGiuseppe JA, Sauvageot, J Epstein JI. Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am J Surg Pathol 21:174-178, 1997.

206. Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathological stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 79:772-779, 1997.

207. Silver RI, Partin AW, Epstein JI, Chan DW, et.al. Prostate specific antigen in men born with bladder exstrophy. Urology 49:253-256, 1997.

208. Wills ML, Hamper UM, Partin AW, Epstein JI. Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens. Urology 49:367-373, 1997.

209. Cina SJ, Epstein JI. Adenocarcinoma of the prostate with atrophic features. Am J Surg Pathol 21:289-295, 1997.

210. Pound CR, Partin AW, Epstein JI, Walsh PC. PSA following anatomical radical retropubic prostatectomy: patterns of recurrence and cancer control Urol Clin N Am 24:395-406, 1997.

211. Gaudin PB, Sesterhenn IA, Wojno KJ, Mostofi FK, Epstein JI. Incidence and clinical significance of high-grade prostatic intraepithelial neoplasia in TURP specimens. Urology 49:558-563, 1997.

212. Thiel R, Pearson JD, Epstein JI, Walsh PC, Carter HB. The role of prostate specific antigen velocity in prediction of final pathological stage in men with localized prostate cancer. Urology 49:716-720, 1997.

213. Cina SJ, Silberman MA, Kahane H, Epstein JI. The diagnosis of Cowper's glands on prostate needle biopsy. Am J Surg Pathol 21:550-555, 1997.

214. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 21:566-576, 1997.

215. Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, Epstein JI, Isaacs WB. An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 56:3814-3822, 1996.

216. Carter HB, Sauvageot J, Walsh PC, Epstein, JI. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol 157:2206-2209, 1997.

217. Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD. Evaluation of appropriate prostate specific antigen (PSA) testing intervals for the detection of curable cancer. JAMA 2271456-1460, 1997.

218. Henneberry JM, Kahane H, Epstein JI. The significance of intraluminal crystalloids in benign prostatic glands on needle biopsy. Am J Surg Pathol 21:725-728, 1997.

219. Oppenheimer JR, Kahane H, Epstein JI. Granulomatous prostatitis on needle biopsy - characterization and clinical correlation of 124 cases. Arch Pathol Lab Med 121: 724-729, 1997.

220. Cadeddu JA, Partin AW, Epstein JI, Walsh PC. Stage D1 (T1-3,N1-3,MO) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy Urology 50:251-255, 1997.

221. Jacobs LB, Brooks JD, Epstein JI. Differentiation of colonic metaplasia from adeno- carcinoma of urinary bladder. Hum Pathol 28:1152-1157, 1997.

222. Epstein JI, Walsh PC, Sauvageot J. Carter HB. Utility of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol 158:1886-1890, 1997.

223. Partin AW, Briggman JV, Subong ENP, Szaro R, Oreper A, Wiesbrock S, Meyer J, Coffey DS, Epstein JI. Preliminary immunohistochemical characterization of a monoclonal antibody (pro:4-216) prepared from human prostate cancer nuclear matrix proteins. Urology 50:800-808, 1997.

224. Halachmi S, De Marzo AM, Linn JF, Epstein JI, Schoenberg MP. Extensive squamous cell carcinoma in situ of the urinary bladder masking deeply invasive disease. J Urol 159: 203, 1997

225. Sauvageot J, Epstein JI. Immunoreactivity for prostate-specific acid phosphatase (PSAP) and prostate-specific antigen (PSA) in adenocarcinoma of the prostate: relation to progression following radical prostatectomy. Prostate 34:29-33, 1998.

226. Kadkol SS, Brody JR, Epstein JI, Kuhajda FP, Pasternack GR. Novel nuclear
     phosphoprotein pp32 is highly expressed in intermediate- and high-grade prostate cancer. Prostate 34:231-237, 1998.

227. Gaudin PB, Rosai J, Epstein JI. Sarcomas and related proliferative lesions of specialized prostatic stroma. Am J Surg Pathol 22:148-162, 1998.

228. Pannek J, Rittenhouse HG, Chan DW, Epstein JI, Walsh PC, Partin AW. The use of percent free PSA for staging of men with clinically localized prostate cancer. J Urol 159:1238-1242,1998.

229. DeMarzo AM, Bradshaw C, Sauvageot J, Epstein JI, Miller GJ. CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate 34:162-168, 1998.

230. Weinstein MH, Greenspan DL, Bhagavan B, Epstein JI. Diagnoses rendered on prostate needle biopsies in community hospitals. Prostate 35:50-55, 1998.

231. Oppenheimer JR, Epstein JI. Partial atrophy in prostate needle cores-another diagnostic pitfall for the surgical pathologist. Am J Surg Pathol 22:440-445, 1998.

232. Wills ML, Sauvageot J, Partin AW, Gurganus R, Epstein JI. Ability of sextant biopsies to predict radical prostatectomy stage. Urology 51:759-764, 1998.

233. Lee BR, Silver RI, Partin AW, Epstein JI, Gearhart JP. A quantitative histologic analysis of collagen subtypes: the primary obstructed and refluxing megaureter of childhood. Urology 51: 820-823, 1998.

234. Carlson GD, Calvanese CB, Kahane H, Epstein JI. Accuracy of biopsy Gleason scores from a large uropathology laboratory that utilizes diagnostic protocol designed to minimize observer variability. Urology 51:525-529, 1998.

235. Brooks JD, Weinstein M, Lin X, Sun Y, Pin SS, Bova GS, Epstein JI, Isaacs WB, Nelson WG. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiology, Biomarkers & Prevention 7:531-536,1998.

236. Pound CR, Walsh PC, Epstein JI, et al. Radical prostatectomy as treatment for PSA-detected stage T1c prostate cancer. World J Urol 15:373-377, 1998.

237. Carter HB, Epstein JI. Prediction of significant cancer in men with stage T1c
     adenocarcinoma of the prostate. World J Urol 15:359-363, 1998.

238. Argani P, Carter HB, Epstein JI. Isolated vasculitis of the seminal vesicle. Urology 52: 31-133, 1998.

239. Epstein JI, Pound CR, Partin AW, Walsh PC. Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol 160:97-101, 1998.

240. Miller L, Partin AW, Chan DW, Sokoll LJ, Dobs AS, Epstein JI, Walsh PC. Influence of radical prostatectomy on serum hormone levels. J Urol 160:449-453, 1998.

241. Andriole GL, Guess HA, Epstein JI, Wise H, Kadom D, Crawford ED, Jackson CL, et al. Treatment with Finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: Results of a randomized, double-blind, placebo-controlled clinical trial. Urology 52:195-202, 1998.

242. Epstein JI. The role of perineural invasion and other biopsy characteristics as prognostic markers for localized prostate cancer. Sem Urol Oncol 16:124-128, 1998

243. Ruska KM, Sauvageot J, Epstein JI. Histology and cellular kinetics of prostatic atrophy. Am J Surg Pathol 22:1073-1077, 1998.

244. De Marzo AM, Meeker AK, Epstein JI, Coffey DS. Prostate stem cell compartments: Expression of the cell cycle inhibitor P27Kip1 in normal, hyperplastic, and cancer cells. Am J Pathol 153:911-919, 1998.

245. Allen EA, Kahane H, Epstein JI. Repeat biopsy strategies for men with atypical diagnoses on initial prostate needle biopsy. Urology 52:803-807, 1998.

246. Argani P, Walsh PC, Epstein JI. Analysis of the prostatic central zone in patients with unilateral absence of wolffian duct structures - further evidence for the mesodermal origin of the prostatic central zone. J Urol 160:2126-2129, 1998.

247. Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, Wolfert R, Carter, HB. Nonpalpable (stage T1C) prostate cancer: Prediction of “insignificant” disease using free/total serum PSA levels and needle biopsy findings. J Urol 160: 2407-2411, 1998.

248. Yang XJ, McEntee M, Epstein JI. Distinction of basaloid carcinoma of the prostate from benign basal cell lesions by using immunohistochemistry for BCL-2 and KI-67. Hum Pathol 29:1447-1450, 1998.

249. Brooks JD, Weinstein M, Lin X, Sun Y, Pin SS, Bova GS, Epstein JI, et.al. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers and Prev 7:531-536, 1998.

250. Epstein JI, Amin MB, Reuter VR, Mostofi FK, and the Bladder Consensus Conference Committee. The World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary Bladder. Am J Surg Pathol 22:1435-1448, 1998.

251. Amin MB, Grignon DG, Bostwick D, Epstein JI, Reuter V, Troncoso P, Ro JY, Ayala AA. Recommendation for reporting resected prostatic carcinomas: Association of Directors of Anatomic and Surgical Pathology: Path Case Rev 3: 223-232, 1998

252. Carducci MA, Piantadosi S, Pound CR, Epstein JI, et.al. Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma. Urology 43:44-49, 1999.

253. Carter HB, Epstein JI, Walsh PC, Partin AW. The influence of age and prostate specific antigen on the chance of curable prostate cancer among men with non- palpable disease. Urology 53:126-130, 1999.

254. Eisenberger CF, Walsh PC, Eisenberger MA, Chow NH, Partin AW, Mostwin JL, Marshall FF, Epstein JI, Schoenberg MP. Incidental non-Hodgkin’s lymphoma in patients with localized prostate cancer. Urology 53:175-179, 1999.

255. Chan TY, Epstein JI. Follow-up of atypical prostate needle biopsies. Urology 53: 351-355, 1999

256. Brat DJ, Wills ML, Lecksell KL, Epstein JI. How often are diagnostic features missed with less extensive histological sampling of prostate needle biopsies? Am J Surg Path 23:257-262, 1999.

257. Yang XJ, Lecksell K, Gaudin P, Epstein JI. Rare expression of high molecular weight cytokeratin in adenocarcinoma of the prostate: A study of 110 cases of metastatic and locally advanced prostate cancer. Am J Surg Pathol 23:147-152, 1999.

258. Marks LS, Partin AW, Dorey FJ, Macairan ML, Garris JB, Gormley FJ, Epstein JI, et.al. Long-term finasteride on prostate tissue composition. Urology 53:574-580, 1999.

259. Yang XJ, Lecksell K, Epstein JI. Does long-term finasteride (PROSCAR) affect the histology of benign prostate tissue and prostate cancer on needle biopsy? Urology 53:696-700, 1999.

260. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI et al. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 53:707-713, 1999.

261. Holmes GF, Walsh PC, Pound CR, Epstein JI. Excision of the neurovascular bundle at radical prostatectomy in cases with perineural invasion on needle biopsy. J Urol 53:752-756, 1999.

262. Green R, Epstein JI. Use of intervening unstained slides for immunohistochemical (IHC) for high molecular weight cytokeratin (HMWCK) on prostate needle biopsies. Am J Surg Pathol 23:567-570, 1999.

263. Epstein JI. How to obtain the maximum diagnostic and prognostic information from prostate needle biopsies. Contemp Urol 11:106-118, 1999.

264. Epstein JI, Partin AW, Shue M, Sherry ED, Marks LS. Histological changes in benign prostate biopsies following long-term, finasteride therapy for benign prostatic hyperplasia. J Urol Path 10:87-95, 1999.

265. Allsbrook WC, Mangold KA, Yang X, Epstein JI. The Gleason grading system: an overview. J Urol Path 10:141-157, 1999.

266. Ruska KM, Partin AW, Epstein JI, Kahane H. Prostate needle biopsy and adenocarcinoma in men under 40 years of age. Urology 53:1179-1183, 1999

267. Lee BR, Roberts WW, Smith D, Ko HW, Epstein JI, Lecksell K, Partin AW. Bioimpedance: Novel use of a minimally invasive technique for cancer localization in the intact prostate. Prostate 39:213-218, 1999

268. Subong ENP, Shue MJ, Epstein JI, Briggman JV, Obar RA, et.al. Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nuclophosmin/B23. Prostate 39:298-304, 1999

269. Baisden BL, Kahane H, Epstein JI. Perineural invasion, mucinous fibroplasia and
     glomerulations: diagnostic features of limited cancer on prostate needle biopsy. Am J Surg Pathol 23:918-924, 1999.

270. Epstein JI, Lecksell K. Carter HB. Prostate cancer sampled on sextant needle biopsy: significance of cancer on multiple cores from different areas of the prostate. Urology 54:291-294, 1999.

271. Yang XJ, Lecksell K, Epstein JI. The significance of small foci of high grade prostate cancer on needle biopsy. Urology 54:528-532, 1999.

272. Allen EA, Burger PC, Epstein JI. Microcystic meningioma arising in a mixed germ cell tumor of the testis: a case report. Am J Surg Pathol 23:1131-1135. 1999.

273. Tickoo SK, Reuter VE, Amin MB, Srigley JR, Epstein JI, Min KW, Rubin MA, Ro JY. Renal oncocytosis: morphologic spectrum and morphogenetic considerations; a study of 12 cases. Am J Surg Pathol 23:1094-1101, 1999.

274. Haussler O, Epstein JI, Amin MB, Heitz PU, Hailemariam S. Putative precursors of prostate cancer - adenosis (atypical adenomatous hyperplasia) and prostatic intraepithelial neoplasia - further investigation of cell kinetics, oncogene and tumor suppressor gene status and comparison with benign prostatic hyperplasia and cancer. Hum Pathol 30:1077-1086, 1999.

275. Allsbrook WC, Jr., Epstein JI. Interobserver reproducibility of Gleason’s grading System for prostatic carcinoma. Japanese J Urol Surg 8:1031-1032, 1999.

276. Epstein JI, Walsh PC, Akingba G, Carter HB. The significance of prior negative needle biopsies in men subsequently diagnosed with prostate cancer. J Urol 162: 1649-1652, 1999.

277. Yang XJ, Lecksell K, Epstein JI. Can immunohistochemistry enhance the detection of micrometastases in pelvic lymph nodes from patients with high grade urothelial carcinoma of the bladder? Am J Clin Pathol 112:649-653, 1999.

278. Brinker DA, Ross JS, Tran TA, Jones DM, Epstein JI. Can ploidy of prostate carcinoma diagnosed on needle biopsy predict radical prostatectomy stage and grade? J Urol 162:2036-2039, 1999.

279. Potter SR, Miller MC, Mangold LA, Jones KA, Epstein JI, et.al. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. Urology 54:791-795, 1999.

280. Pannek J, Yegappan L, Pound CR, Lemkin PG, Epstein JI, et.al. Nuclear shape and nuclear matrix protein composition in prostate and seminal vesicles. Urology 54:934-939, 1999.

281. Hurwitz MD, DeWeese TL, Zinreich ES, Epstein JI, Partin AW. Nuclear morphometry predicts disease free interval for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy. Int J Cancer 84: 594-597, 1999.

282. Kronz JD, Westra WH, Epstein JI. Mandatory second opinion surgical pathology at a large referral hospital. Cancer 86:2426-2435, 1999.

283. Brinker DA, Potter SR, Epstein JI. Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. Am J Surg Pathol 23:1471-1479, 1999.

284. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy (PIA) of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 155:1985-1992, 1999.

285. Pannek J, Berges RR, Sauvageot J, Lecksell KL, Epstein JI, Partin AW. Cell turnover in human seminal vesicles and the prostate: an immunohistochemical study. Prostate Cancer and Prostatic Diseases 2:200-203, 1999.

286. Reuter VR, Epstein JI, Amin MB, Mostofi FK, and the Bladder Consensus Conference Committee. A newly illustrated synopsis of the World Health Organization/International Society of Urological Pathology (WHO/ISUP) Consensus Classification of urothelial (transitional-cell) neoplasms of the urinary bladder. J Urologic Pathology 11:1-27, 1999.

287. Berman DM, Yang J, Epstein JI. Foamy gland high grade prostatic intraepithelial neoplasia. Am J Surg Pathol 24:140-144, 2000.

288. Westra WH, Grenko RT, Epstein JI. Solitary fibrous tumor of the lower urogenital tract: A report of five cases involving the seminal vesicles, urinary bladder, and prostate. Hum Pathol 31:63-68, 2000.

289. Pan C-C, Potter SR, Partin AW, Epstein, JI. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system Am J Surg Pathol 24:563-569, 2000.

290. Fritsch M, Epstein JI, Perlman E, Watts J, Argani P. Molecularly confirmed primary prostatic synovial sarcoma. Hum Pathol 31:246-250, 2000.

291. Halachmi S, De Marzo, AM, Halachmi N, Smith AE, Linn JF, Epstein JI, Sidransky D, Schoenberg M. Genetic alterations in human bladder carcinosarcoma. Eur Urol 37:350-357, 2000.

292. Weir EG, Partin AW, Epstein JI. Correlation between serum levels of prostate specific antigen (PSA) and quantitative PSA immunohistochemistry. J Urol 163:1739-1742, 2000.

293. Ripple MG, Potter SR, Partin AW, Epstein JI. Needle biopsy of recurrent adenocarcinoma of the prostate following radical prostatectomy. Mod Pathol 13:521-527, 2000.

294. Brinker DA, Amin MB, de Peralta-Venturina M, Reuter V, Chan DY, Epstein JI. Extensively necrotic cystic renal cell carcinoma: A clinicopathologic study with comparison to other cystic and necrotic renal cancers. Am J Surg Pathol 24: 988-995, 2000.

295. Marks LS, Partin AW, Epstein JI, et al. Effects of saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 163:1451-1456, 2000.

296. Oliva E, Quinn TR, Amin MB, Eble JN, Epstein JI, Srigley JR, Young RH. Primary malignant melanoma of the urethra. A clinicopathologic analysis of 15 cases. Am J Surg Pathol 24:785-796, 2000.

297. Epstein JI, Partin AW, Potter SR, Walsh PC. Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters. Urology 56:283-288, 2000.

298. Levi AW, Epstein JI. Pseudohyperplastic prostatic adenocarcinoma on needle biopsy & simple prostatectomy. Am J Surg Pathol 24:1039-1046, 2000.

299. Argani P, Faria PA, Epstein JI, Reuter VE, Perlman EJ, Beckwith B, Ladanyi M. Primary renal synovial sarcoma: Molecular and morphologic delineation of an entity previously included among embryonal sarcomas of the kidney. Am J Surg Pathol 24:1087-1096, 2000.

300. Potter SR, Epstein JI, Partin AW, MD, Ph.D. Seminal vesicle invasion by prostate
     cancer: Prognostic significance and therapeutic implications. Rev Urol 2:190-195, 2000.

301. Tomaszewski JE, Bear HD, Connally JA, Epstein JI, et al. Consensus conference on second opinions in diagnostic anatomic pathology. Am J Clin Pathol 114:329- 336, 2000.

302. Kronz JD, Silberman MA, Allsbrook WC Jr., Bastacky SI, Burks RT, Cina SJ, Mills SE, Ross JS, Sakr WA, Tomaszewski JE, True LD, Ulb right TM, Weinstein MW, Yantiss RK, Young RH, Epstein JI. Pathology residents’ use of a web-based tutorial to improve Gleason grading of prostate carcinoma on needle biopsies. Hum Pathol 31:1044-1050, 2000.

303. Dardik M, Epstein JI. Efficacy of restaining prostate needle biopsies with high molecular weight cytokeratin. Hum Pathol 31:1155-1161, 2000.

304. Pan CC, Chiang H, Chang YH, Epstein JI. Tubulocystic clear cell adenocarcinoma arising within the prostate. Am J Surg Pathol 24:1433-1436, 2000.

305. Milord RA, Kahane H, Epstein JI. Infarct of the prostate gland: Experience on needle biopsy specimens. Am J Surg Pathol 24:1378-1384, 2000.

306. Kronz JD, Silberman MA, Allsbrook WC, Jr., Epstein JI. A web-based tutorial improves practicing pathologists’ Gleason grading of prostate cancer on needle biopsies: Validation of a new medical education paradigm. Cancer 89:1818-1823, 2000.

307. Chan TY, Partin AW, Walsh PC, Epstein JI. The prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 56:823-827, 2000.

308. Han M, Snow PB, Epstein JI, Chan TY, Jones KA, Walsh PC, Partin AW. A neural network predicts progression for men with Gleason score 3+4 versus 4+3 tumors following radical prostatectomy. Urology 56:994-999, 2000.

309. Chow NH, Cairns P, Eisenberger CF, Schoenberg MP, Taylor DC, Epstein JI, Sidranky D. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder. Int J Cancer 89:514-518, 2000.

310. Potter SR, Mangold LA, Shue MJ, Taylor DC, Lecksell K, Epstein JI, et al. Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative lymph nodes at radical prostatectomy. Cancer 89:2577-2586, 2000.

311. Inpakala S, Snow PB, Marks LS, Christens-Barry WA, Epstein JI, Bluemke DA, Partin AW. Neural network prediction of prostate tissue composition based on magnetic resonance imaging analysis. A pilot study. Analyt Quant Cytol Histol 22:445-452, 2000.

312. Allsbrook WC Jr., Mangold KA, Johnson MH, Lane RB, Lane CG, Amin MB, Bostwick DG, Humphrey PA, Jones EC, Reuter VE, Sakr W, Sesterhenn IA, Troncoso P, Wheeler TM, Epstein JI. Interobserver reproducibility of Gleason grading of prostatic carcinoma. I. Urologic pathologists. Hum Pathol 32:74-80, 2001.

313. Allsbrook WC, Jr., Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI. Interobserver reproducibility of Gleason grading of prostatic carcinoma. II. General Pathologists. Hum Pathol 32:81-88, 2001.

314. Kronz JD, Shaikh AA, Epstein JI. Atypical cribriform lesions on prostate biopsy. Am J Surg Path 25:147-155, 2001.

315. Han M, Pound CR, Potter SR, Partin AW, Epstein JI, Walsh PC. Isolated local recurrence is rare following radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins: therapeutic implications. J Urol 165:864-866, 2001.

316. Potter SR, Epstein JI, Partin AW. What are the implications of perineural invasion on prostate biopsy? Contemporary Urol:21-26, 2001.

317. Jimenez RE, Eble JN, Reuter VE, Epstein JI, Folpe AL, et al. Concurrent angiomyolipoma and renal cell neoplasia: a study of 36 cases. Mod Pathol 14:157-163, 2001.

318. Epstein JI. Pathologists and the judicial process: How to avoid it. Am J Surg Pathol 25:527-537, 2001.

319. Cina SJ, Lancaster-Weiss KJ, Lecksell K, Epstein JI. Correlation of ki-67 and p53 with the new WHO/ISUP classification system for urothelial neoplasia. Arch Pathol Lab Med 125:646-651, 2001.

320. Han M, Piantadosi P, Zahurak ML, Sokoll LJ, Chan DW, Epstein JI, Walsh PC, Partin AW. Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology 57:707-11,2001.

321. Bova GS, Parmigiani G, Epstein JI, Wheeler T, Mucci NR, Rubin MA. Web- based tissue microarray image data analysis: initial validation testing through prostate cancer Gleason grading. Hum Pathol 32:417-427, 2001.

322. Kronz JD, Shaikh AA, Epstein JI. High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands (PINATYP) on prostate biopsy. Hum Pathol 32:389-395, 2001.

323. Marks LS, Epstein JI, Partin AW. The role of needle biopsy in evaluation of chemopreventive agents. Urology 57:191-193, 2001.

324. Epstein JI, Walsh PC, Carter HB. The importance of posterolateral needle biopsies in the detection of prostate cancer. Urol 57:1112-1116,2001.

325. Roberts WW, Carducci M, Han M, Epstein JI, Eisenberger MA, Walsh PC, Partin AW. Contemporary identification of patients at high-risk for early prostate cancer recurrence following radical retropubic prostatectomy. Urol 57:1033-1037, 2001.

326. Allen CH, Epstein JI. Nephrogenic adenoma of the prostatic urethra: a mimicker of prostate adenocarcinoma. Am J Surg Pathol 25: 802-808, 2001.

327. Oliai BR, Kahane H, Epstein JI. A clinicopathologic analysis of urothelial carcinomas diagnosed on prostate needle biopsy. Am J Surg Pathol 25:794-801, 2001.

328. Smith Sehdev AE, Pan CC, Epstein JI. Comparative analysis of sampling methods in nonpalpable (stage T1C) radical prostatectomy specimens. Hum Pathol 32:494- 499, 2001.

329. Parwani AV, Husain AN, Epstein JI, Beckwith JB, Argani P. Low grade myxoid renal carcinomas with distal nephron differentiation. Hum Pathol 32:506-512,2001.

330. Cina SJ, Epstein JI, Endrizzi JM. et al. Correlation of cystoscopic impression with histologic diagnosis of biopsy specimens of the bladder. Hum Pathol 32;630-637, 2001.

331. Chan TY, Epstein JI. In-situ adenocarcinoma of the bladder. Am J Surg Pathol 25:892-899, 2001.

332. Han M, Partin AW, Piantiadosi S , Epstein JI, Walsh PC. Era-specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 166:416-419, 2001.

333. Levi AW, Potter SR, Schoenberg MP, Epstein JI. Clinical significance of denuded urothelium in bladder biopsies. J Urol 166:457-460,2001.

334. Epstein JI, Potter SR. The pathologic interpretation and significance of prostate biopsy findings: Implications and current controversies. J Urol 166: 402-410, 2001.

335. Kronz JD, Allan CH, Shaikh AA, Epstein JI. Predicting cancer following a diagnosis of high grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol 25:1079-1085,2001.

336. Montgomery E, Goldblum JR, Epstein JI, Fisher C. Leiomyosarcomas of the paratesticular region: a clinicopathologic study. Am J Surg Pathol 25;1143-1149, 2001.

337. Epstein JI. Pathological assessment of the surgical specimen. Urologic Clinics of North America 28:567-594, 2001.

338. Yaycioglu O, Roberts WW, Chan T, Epstein JI, et al. Prognostic assessment of non-metastatic renal cell carcinoma: a clinically based model. Urology 58:141-145,2001.

339. Milord RA, Lecksell K, Epstein JI. An objective morphologic parameter for the diagnosis of flat urothelial neoplasms: Urothelial to lymphocyte upper quartile nuclear ratio. Hum Pathol 32:997-1002, 2001.

340. Epstein JI, Walsh PC, Carter HB. Is there dedifferentiation of prostate cancer grade over time in men followed expectantly for stage T1C disease? J Urol 166:1688-1691, 2001.

341. Chan TY, Chan DY, Lecksell K, Stutzman RE, Epstein JI. Does increased needle biopsy sampling of the prostate detect a greater number of potentially insignificant tumors? J Urol 166:2181-2184, 2001.

342. Barocas DA, Han M, Epstein JI, Chan DY, Walsh PC, Partin AW. Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer? Urology 58:746-751, 2001.

343. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: The 15-year Johns Hopkins experience. Urol Clin North Am 28:555-65, 2001.

344. Argani P, Epstein JI. Inverted (hobnail) high-grade prostatic intraepithelial neoplasia (PIN): Report of fifteen cases of an hitherto undescribed pattern of high-grade PIN. Am J Surg Pathol 25:1534-1539, 2001.

345. Rioux-Leclercq N, Patard J, Epstein JI, Alva A, Bensalah, Bansard J, Lobel B. Impact of CD44H expression on the prognosis of locally confined renal cell carcinoma. J Urol Pathol 13:85-94, 2000.

346. Rioux-Leclercq N, Epstein JI, Bansard J, Turlin B, Patard J, Manunta A, Chan T, Rameee M, Lobel B, Moulinoux J. Clinical significance of cell proliferation, microvessel density and CD44 adhesion molecule expression in renal cell Carcinoma. Hum Pathol 32:1209-1215, 2001.

347. Partin AW, Mangold LA, Lann DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for new millennium. Urology 58:843-848, 2001.

348. O’Malley KJ, Pound CR, Walsh PC, Epstein JI, Partin AW. The influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy. Urology 59:85-90, 2002.

349. Rioux-Leclercq N, Epstein JI. Unusual morphologic patterns of basal cell hyperplasia of the prostate. Am J Surg Pathol 26:237-243, 2002.

350. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of prostate cancer with curative intent: Preliminary results. J Urol 167;1231-1234, 2002.

351. Gillespie JW, ……. Epstein JI, et al. Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol 160:449-457, 2002.

352. Seibel JL, Epstein JI. Villous adenoma of the urinary tract: a lesion capable of divergent differentiation and frequently associated malignancy. Hum Pathology 33:236-241,2002.

353. Swierczynski SL. Epstein JI. Prognostic significance of atypical papillary urothelial hyperplasia. Hum Pathol 33; 512-517, 2002.

354. Srodon M, Epstein JI. Central zone histology of the prostate: A mimicker of high grade prostatic intraepithelial neoplasia. Hum Pathol 33:518-523, 2002.

355. Makarov DV, Sanderon H, Partin AW, Epstein JI. Gleason score 7 on needle biopsy: Is the prognostic difference between Gleason scores 4+3 and 3+4 independent of the number of involved cores? J Urol 167:2440-2442,2002.

356. Veltri RW, Miller MC, Mangold LA, O’Dowd GJ, Epstein JI, Partin AW. Prediction of pathological stage in clinical stage T1c prostate cancer patients: The new challenge. J Urol 168:100-4, 2002.

357. Samaratunga H, Makarov DV, Epstein JI. Comparison of WHO/ISUP and WHO classification of non-invasive papillary urothelial neoplasms for risk of progression. Urology. 60:315-319,2002.

358. Haese A, Epstein JI, Huland H, Partin AW. Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate cancer: Impact on changing treatment modalities. Cancer 95:1016-1021, 2002.

359. Viglione MP, Potter S, Partin AW, Lesniak MS, Epstein JI. Should the diagnosis of “benign prostatic hyperplasia” be made on prostate needle biopsy? Hum Pathol 33:796-800,2002.

360. Oliai BR, Kahane H, Epstein JI. Can basal cells be seen in adenocarcinoma of the prostate? An immunohistochemical study using high molecular weight cytokeratin. Am J Surg Pathol 26:1151-1160, 2002.

361. Rioux-Leclercq NC, Chan DY, Epstein JI. Prediction of outcome after radical prostatectomy in men with organ-confined Gleason score 8-10 adenocarcinoma. Urology 60:666-669, 2002.

362. Veltri RW, Marks LS, Miller MC, Bales WD, Fan J, Epstein JI, Partin AW. Saw Palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: Evidence for a possible molecular mechanism. Urology 60:616-621, 2002.

363. Sokoll LJ, Mangold LA, Partin AW, Epstein JI, BruzekDJ, Dunn W, Mohr P, Wallerson G, Chan DJ. Complexed prostate-specific antigen as a staging tool for prostate cancer: A prospective study in 420 men. Urology 60 (suppl 4A): 18-23, 2002.

364. Gretzer MB, Epstein JI, Pound CR, Walsh PC, Partin AW. Substratification of stage T1c prostate cancer based on the probablility of biochmemical recureence. Urology 60: 1034-1039, 2002

365. Han M, Lai S, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (Prostate specific antigen) recurrence following radical prostatectomy for clinically localized prostate cancer. J Urol 169 (March):517-523, 2003.

366. Magi-Galluzzi C, Sanderson H, Epstein JI. Atypia in non-neoplastic prostate glands after radiotherapy for prostate cancer: Duration of atypia and relation to type of radiotherapy. Am J Surg Pathol 27 (Feb):206-212, 2003.

367. Kronz JD, Milord R, Wilentz R, Weir EG, Schreiner SR, Epstein JI. Lesions missed on prostate biopsies in cases sent in for consultation. Prostate 54 (March):310-314, 2003.

368. Rioux-Leclercq NC, Epstein JI. Renal cell carcinoma with intratumoral calcium oxalate crystal deposition in patients with acquired cystic disease of the kidney. Arch Path Lab Med 127 (Feb): E89-92, 2003.

369. Harden SV, Guo Z, Epstein JI, Sidransky D. Quantitative GSTP1 methylation clearly distinguishes between benign prostatic tissue and limited prostate adenocarcinoma. J Urol 169 (March): 1138-1142, 2003.

370. Haese A, Chaudhari, Miller MC, Epstein JI, ……, Veltri RW. Quantitative biopsy pathology for prediction of pathologically organ confined prostate cancer: A multiinstitutional validation study. Cancer 97 (Feb): 969-78, 2003.

371. Epstein JI. The new world health organization/international society of urological pathology (who/isup) classification for ta, t1 bladder tumors: is it an improvement? Critical Reviews in Oncology/Hematology (in press).

372. Allen EA, Brinker DA, Coppola D, Diaz JI, Epstein JI. Multilocular prostatic cystadenoma with focal high-grade prostatic intraepithelial neoplasia: a case report and review of the literature. Urology (in press).

373. Magi-Galluzzi C., Luo J, Isaacs WB, Hicks JL, DeMarzo AM, Epstein JI. Alpha- methylacyl-coa-racemase (AMACR): A variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am J Surg Pathol (in press).

374. DeMarzo A, Nelson WG, Isaacs WB, Epstein JI. Pathology and molecular aspects of prostate cancer. Lancet (in press).

375. Zhou M, Jiang Z, Epstein JI. Expression and diagnostic utility of alpha-methylacyl-
     coa-racemase in foamy gland & pseudohyperplastic prostate cancer. Am J Surg Pathol (in press).

376. Weir E, Epstein JI. Identification of small lymphocytic lymphoma at radical prostatectomy. (submitted).

377. Haddadin MH, Hawkins AL, ….. Epstein JI, Griffin CA. Cytogenetic study of malignant triton tumor: A case report (Submitted).

378. Mikami Y, Epstein JI, Furusato M, Matsuno Y, Manabe T, Shiraishi T, Tsuzuki T. Accuracy of Gleason grading by practicing pathologists an the impact of education for improving agreements. Human Pathol (submitted).

379. Kunz GM Jr., Epstein JI. Should each core with prostate cancer be assigned a separate Gleason score? Am J Surg Pathol (submitted).

380. Tsuzuki T, Epstein JI. Fibroepithelial polyp of the lower urinary tract in adults. Am J Surg Pathol (submitted).

381. Magi-Galluzzi C, Epstein JI. Threshold for diagnosing prostate cancer over time. Hum Pathol (submitted).

382. Allan RW, Sanderson H, Epstein JI. Minute adenocarcinoma on prostate needle biopsy: Correlation with radical prostatectomy. J Urol (submitted).
     

383. Khan MA, Han M, Partin AW, Epstein JI, Walsh PC. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003 (submitted).

384. Volmar KE, Chan TY, DeMarzo AM, Epstein JI. Florid von Brunn nests mimicking urothelial carcinoma: A morphologic and immunohistochemical comparison to the nested variant of urothelial carcinoma. (submitted).

385. Parwani AV, Levi AW, Epstein JI, Ali SZ. Urinary bladder with denuded mucosa – “Denuding Cystitis”: Clinicopathologic correlates. (submitted).

386. Harden SV, Sanderson H, Goodman SN, Partin AW, Walsh PC, Epstein JI, Sidransky D. Quantitative GSTPI methylation improves the detection of prostate Adenocarcinoma in sextant biopsies. JNCI (in press).

387. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG, DeMarzo AM. Hypermethylation of the human GSTP1 CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: A detailed study using laser-capture microdissection. (submitted).

388. Khan MA, Carter HB, Epstein JI, Miller MC, Landis P, Walsh PC, Partin AW, Veltri RW. Can clinical and pathological parameters predict significant change in expectant management criteria in a prostate cancer patient cohort? (submitted).

389. Khan MA, Partin AW, Mangold LA, Epstein JI, Walsh PC. The probablility of biochemical recurrence by final pathologic stage for localized prostate cancer. (submitted).

1. Epstein JI , Eggleston JCE: Interpretation and evaluation of the pathologic grade, stage and margins of resection in adenocarcinoma of the prostate. American Urology Association Update Series: 2-8, l986.

2. Epstein JI , Walsh PC. Stage A prostate cancer is incidental but not insignificant: Data to support radical prostatectomy for young men with stage Al disease in Problems in Prostatic Cancer Control. Paulson DF (Consultant Ed.). Philadelphia: J.B. Lippincott, l987: 34-41, (Paulson DF, ed. Problems in Urology: Vol.l).

3. Walsh PC, Epstein JI . Potency following radical prostatectomy with wide unilateral excision of the neurovascular bundle in Problems in Prostatic Cancer Control. Paulson DF. (Consultant Ed.) Philadelphia: J.B. Lippincott, l987: 42-52. (Paulson DF, Ed. Problems in Urology: Vol.l).

4. Epstein JI : Disorders of the prostate gland. In: Diagnosis in Surgical Pathology. Edited by S.S. Sternberg, New York: Raven Press 1989:1293-1432.

5. Epstein JI : Spermatic cord and paratesticular tissues. In: Urologic Pathology, Edited by Murphy W.M. Philadelphia: W.B. Saunders 1989:219-248.

6. Epstein JI , Walsh PC. The classification and prognosis of untreated stage A1 and A2 prostate cancer with a comparison of their findings at radical prostatectomy. In: A multidisciplinary analysis of con- troversies in the management of prostate cancer. Edited by D.S. Coffey, MI Reasnick, FA Dorr, and JP Karr. New York: Plenum Press,1988: 41-45.

7. Epstein JI : Tissue levels of prostate-specific antigen in the non- neoplastic and neoplastic prostate gland. In: Clinical Aaspects of Prostate Cancer. Edited by WJ Catalona, DS Coffey, JP Carr. New York: Elsevier Science Publishing Co.,1989:190-196.

8. Epstein JI : The classification, prognosis, and treatment of stage A (incidental) prostate carcinoma. In: Progress in Reproductive and Urinary Tract Pathology. Edited by Damjanov I, Philadelphia: W.W. Norton and Co. 1989:101-111.

9. Eble JN, Epstein JI : Stage A carcinoma of the prostate. In: Pathology of the prostate, seminal vesicles, and male urethra. Bostwick DG (consultant ed.) New York: Churchill Livingstone, (Roth LM, ed.) Contemporary issues in Surgical Pathology, 1990:61-82.

10. Epstein JI , Hill GS. Tumors of the prostate. In: Urinary Tract Pathology: An Illustrated Practical Guide to Diagnosis. New York, NY: Raven Press, 1992. Bernstein J and Churg J, eds.

11. Epstein JI . Controversies in Prostate Pathology: Dysplasia or Carcinoma In-Situ. In IAP monograph on Pathology and Pathobiology of the Urinary Bladder and Prostate. Baltimore, MD: Williams and Wilkins, 1992. Weinstein RS and Gardner WA,Jr., eds.

12. Partin AW, Carter HP, Epstein JI , Coffey DS. The biology of prostate cancer: New and future directions in predicting tumor behavior. In IAP Monograph in Pathology and Pathobiology of the Urinary Bladder and Prostate. Baltimore, MD: Williams and Wilkins, 1992. Weinstein RS and Gardner WA,Jr., eds.

13. Epstein JI . Surgical margins in patients with carcinoma of the prostate. American Urol Assoc Update Series13:54-59, 1994.

14. Epstein JI : Disorders of the prostate gland. In: Diagnosis in Surgical Pathology. Second edition. Edited by S.S. Sternberg, New York: Raven Press 1993:1807-1853.

15. Wu TC, MacMahon EME, Zhang J, Lambe B, Charache P, Mann RB, Epstein JI , Hayward SD, Ambinder RF: EBER1 small nuclear RNA in malignancy: A morphologically distinctive target for detection of EBV in formalin- fixed paraffin-embedded specimens. In Epstein-Barr virus and human disease 1990. Ablashi DV, ed. Clifton, New Jersey: Humana Press 1991:163-167

16. Epstein JI . Grading of prostatic adenocarcinomas. In: Questions and Uncertainties in prostate cancer. Edited by W.B Peeling, London: Blackwell Science 1996; 81-96.

17. Epstein JI . Nonpalpable Preneoplastic Lesions of the Prostate. In: Principles and practice of genitourinary oncology. Edited by Raghavan D, Scher HI, Leibel SA, Lange P, Philadelphia: J.B. Lippincott 1997;387-394.

18. Epstein JI : Non-neoplastic diseases of the prostate. In: Urologic Surgical Pathology. Edited by D.G. Bostwick and J.N. Eble, St. Louis, Mosby 1997:307-340.

19. Epstein JI Pathology of adenocarcinoma of the prostate. In: Campbell's Urology. Edited by Walsh PC, Retik AB, Vaughan ED Jr., Wein AJ, Philadelphia: W.B. Saunders, 1998:2497-2505.

20. Epstein JI. Pathologic features that predict progression of disease following radical prostatectomy. In: Pathology of the Prostate, Edited by Foster C, Bostwick DG, Philadelphia; W.B. Saunders, 1997:228-244.

21. Epstein JI , Murphy WM. Diseases of the prostate gland and seminal vesicles. In: Urologic Pathology (2nd ed), edited by Murphy WM, Philadelphia, W.B. Saunders 1997: 148-241.

22. Gaudin PB, Epstein JI . Diseases of the spermatic cord and paratesticular tissue. In: Urologic Pathology (end ed), Edited by Murphy WM, Philadelphia: W.B. Saunders 1997: 242-276.
    
    
23. Prostate Cancer: Treatment guidelines for patients. The National Comprehensive
    Cancer Network. Version II. January 2,001.
    
    
24. Epstein JI. Pathology. In: Prostate Cancer: Principles and Practice. Edited by
    Kantoff, PW, Carroll, PR, and D’Amico AV, Philadelphia: Lippincott William & Wilkins 2002: 232-253.
    
    
25. Epstein JI. Diseases of The Lower Urinary System and Male Genitourinary System.
    In: Robbins Pathologic Basis of Disease. Edited by Kumar V, Abbas A, Fausto N.
    Philadelphia: W.B. Saunders, 7 Edition. (in press).
    

1. Epstein JI : Interpretation of Prostate Biopsies. Raven Press, New York, 1989.

2. Epstein JI : Differential Diagnoses in Pathology: Urologic Disorders. Igaku-Shoin, New York, 1992.

3. Murphy WM, Epstein JI . Urological Pathology. ASCP Press, Chicago, 1995.

4. Epstein JI : Interpretation of Prostate Biopsies. 2nd Edition. Raven Press, New York (1996).
   
   
5. Epstein JI: Interpretation of Prostate Biopsies. 3rd Edition. Lippincott William and
   Wilkins, New York (2002).
   
   
6. Eble JN, Epstein JI, Sauter G, Sesterhenn I. WHO Classfication of Tumours :
   Pathology and Genetics. Tumours of the Urinary and Male Reproductive System
   IARC Press, Lyon France (2003)